Sort   by:  
 Page size 
ProteomicsOmentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment
High-grade serous (HGS) ovarian cancer is the most lethal gynaecological disease in the world and metastases is a major cause. The omentum is the preferential metastatic site in HGS ovarian cancer patients and in vitro models that recapitulate the original environment of this organ at cellular and m...
ORGANISM(S): Mus musculus (Mouse) 
2023-11-28 | PXD045024 | Pride
Extracellular matrix  ovarian cancer  caf  matrisome  omentum 
ProteomicsOmentum gel enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment
High-grade serous (HGS) ovarian cancer is the most common and aggressive ovarian cancer type, and the most lethal gynaecological disease 1,2. The major cause is its highly metastatic nature and the limited availability of effective therapies to oppose it. The omentum is a highly vascularised viscera...
ORGANISM(S): Homo sapiens (Human) 
2023-11-28 | PXD042317 | Pride
Extracellular matrix  ovarian cancer  caf  matrisome  omentum 
ProteomicsOmentum gel enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment
High-grade serous (HGS) ovarian cancer is the most common and aggressive ovarian cancer type, and the most lethal gynaecological disease 1,2. The major cause is its highly metastatic nature and the limited availability of effective therapies to oppose it. The omentum is a highly vascularised viscera...
ORGANISM(S): Homo sapiens (Human) 
2023-11-28 | PXD042320 | Pride
Extracellular matrix  ovarian cancer  caf  matrisome  omentum 
UnknownEffect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial.
Not available
S-EPMC8787685 | biostudies-literature
UnknownAntiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Not available
S-EPMC4481320 | biostudies-literature
UnknownDevelopment and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Not available
S-EPMC5408574 | biostudies-literature
UnknownTwelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Not available
S-EPMC4481318 | biostudies-literature
UnknownEffect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132 | biostudies-literature
UnknownEffect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC10326520 | biostudies-literature
UnknownSimvastatin in Critically Ill Patients with Covid-19.
Not available
S-EPMC10755839 | biostudies-literature
Sort   by:  
 Page size